Outlook Pulls Bevacizumab BLA As Filing Falls Short

Plans To Submit Revised US Application With FDA In Q3

Pinning its hopes on its proposed bevacizumab product for ophthalmic indications, Outlook Therapeutics has been told to give more information to the US FDA ahead of an approval. However, one analyst remained upbeat for the company’s prospects.

Eye
Is an ophthalmic bevacizumab coming soon? • Source: Shutterstock: Prostock-studio

Outlook Therapeutics’ plans to repurpose bevacizumab for the treatment of wet age-related macular degeneration have been dealt a setback, with the US Food and Drug Administration telling the firm that it requires additional information to complete filing of the company’s biologics license application.

The New Jersey-based player had filed its BLA for its proposed Lytenava (bevacizumab-vikg) asset in March this year. It envisions...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.